PTC Therapeutics Raises 2026 Product Revenue Outlook, Now $960 Million to $990 Million
Photo: TokenPost
PTC Therapeutics, Inc. (PTCT) raised its 2026 product revenue outlook to $960 million to $990 million and expects to complete the rolling biologics license application (BLA) submission for ST-920 in Q4 2026. The company projects total revenue of $1.29 billion to $1.32 billion for 2026. Management also expects PTC to reach cash flow breakeven in 2026. Sephience remains in the early stages of launch, with more than 2,000 active patients. Management said most eligible U.S. patients have yet to try the treatment and expressed confidence in peak sales potential above $2 billion.
Source: TokenPost
